ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies worldwide. The company offers allergy immunotherapy products as injections, sublingual drops, and sublingual tablets for various allergies, including grass, ragweed, house dust mite, tree, cat, bee, and wasp. It also offers adrenaline auto-injectors for the treatment of severe allergic reactions. In addition, the company’s development programs include GRAZAX for grass allergic (ARC) and asthma prevention; GRASTEK for grass ARC; RAGWITEK for ragweed ARC; house dust mite (HDM) sublingual tablet-based allergy immunotherapy (SLIT)-tablets for HDM asthma and rhinitis; tree SLIT-tablet for tree ARC; and Japanese cedar SLIT-tablet for cedar tree ARC. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.
alk-abello a/s (AKBLF:Grey Market)
Bøge Allé 6-8
Phone: 45 45 74 75 76
Fax: 45 45 74 86 07www.alk-abello.com
|Allergy Therapeutics PLC||23.50 GBp||0.00|
|DBV Technologies SA||€52.75 EUR||-1.51|
|Merck & Co Inc||$57.67 USD||+0.07|
|Stallergenes SA||€52.50 EUR||-2.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.